Last reviewed · How we verify
NCT03522038: FAGA-CTO
Functional Assessment-guided Angioplasty in Patients With Coronary Chronic Total Occlusion
trial testing percutaneous coronary intervention in Coronary Occlusion in 300 participants. Status unknown.
31 December 2019
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 August 2018 |
| Primary completion | 31 December 2019 |
| Estimated completion | 30 June 2020 |
Drugs / interventions tested
- percutaneous coronary intervention
Conditions studied
- Coronary Occlusion — all drugs for Coronary Occlusion →
- Angioplasty, Balloon, Coronary — all drugs for Angioplasty, Balloon, Coronary →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Adults 18 to 80, any sex, with Coronary Occlusion or Angioplasty, Balloon, Coronary. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate the role of functional evaluation for predicting clinical outcome in patients with coronary chronic total occlusion (CTO) undergoing percutaneous coronary intervention (PCI), and to evaluate the clinical evidence for the using of fractional flow reserve (FFR), coronary flow reserve (CFR), index of myocardial resistance (IMR) and dynamic single photon emission computed tomography (D-SPECT) in these patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03522038
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of percutaneous coronary intervention
Trials testing the same drug.
- NCT07444346 — Intravascular Imaging-Guided Intravascular Lithotripsy for Severe Coronary Calcified Lesions. · not yet recruiting
- NCT07297641 — Intravascular Imaging-Guided Versus Angiography- Guided PCI in Patients With DES-ISR · recruiting
- NCT07312318 — AI-Driven Dynamic Prediction of Non-Target Lesion Progression After PCI: A Chinese Multicenter Cohort Study · recruiting
- NCT06853470 — Prospective Evaluation for Receiving SynFlow 3.0 Interventional Circulatory Support in High-risk PCI: A Randomized Contr · NA · completed
- NCT05883579 — Application of Coronary Artery Chronic Total Occlusion Scoring Systems · unknown
Other recruiting trials for Coronary Occlusion
Currently open trials in the same condition.
- NCT06878729 — Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI · NA · recruiting
- NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
- NCT06542393 — PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG) · Phase 2 · recruiting
- NCT06681584 — Comparison of the Diagnostic Performance and Costs of FFRB Vs. Standard Care in Suspected Coronary Artery Disease. · active not recruiting
- NCT04604197 — ANGiographic Evaluation of Left Main Coronary Artery INtErvention · NA · active not recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03522038 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 11 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03522038.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing